Sagent Pharmaceuticals, Inc.
Schaumburg, IL
- UEI
- PR1HCLM3FMW7
- CAGE
- 4RP13
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1515 Woodfield Rd Suite 1100, Schaumburg, IL 60173, USA
- Website
- sagentpharma.com
- Founded
- 2007
- Employees
- 51-250
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $426,599 |
| FY2025 | $16,741,169 |
| FY2024 | $220,120 |
| FY2023 | $189,719 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $275,580 | |
| 2 | Defense Logistics Agency | $151,019 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Fresenius Kabi, LLC | Lake Zurich, IL | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| FKA West-Ward Pharmaceuticals | Berkeley Heights, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Bayer Healthcare Pharmaceuticals Inc. | Hanover, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Allscripts Medication Services Group | Libertyville, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Prasco, LLC | Mason, OH | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Sagent Pharmaceuticals, Inc., headquartered in Schaumburg, Illinois, manufactures and supplies injectable pharmaceutical products to the federal government as a prime contractor across defense, civilian health, and disaster-preparedness agencies. The company competes on full-and-open terms without SBA set-aside designations and operates across a portfolio of 331 prime awards with combined potential value of $331.3 million, of which $143.1 million has been obligated.
Sagent's capability footprint centers on injectable antibiotics (levofloxacin, ciprofloxacin, cefepime, ampicillin-sulbactam, metronidazole), critical care medications (adenosine, propofol), and anesthesia products. Representative contracts include a $47.8 million delivery order from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (awarded September 26, 2022) for ciprofloxacin 5% dextrose injection as a Strategic National Stockpile medical countermeasure, running through December 31, 2024; a $16.6 million firm fixed-price delivery order from HHS ASPR (awarded September 30, 2025) for ciprofloxacin solution for injection 400 mg/200 ml flexi-bag through September 30, 2026; and a $1.3 million purchase order from the Department of Veterans Affairs Veterans Integrated Service Network 12 (awarded August 14, 2026) for ciprofloxacin intravenous piggyback through August 28, 2030.
Customer concentration is pronounced. The Defense Logistics Agency Troop Support Medical dominates by award count with 303 awards and $69.5 million combined potential value, reflecting steady small-dollar delivery orders for routine pharmaceutical supply. However, potential-value leadership rests with HHS Centers for Disease Control and Prevention Pittsburgh (9 awards, $158.5 million combined potential value) and HHS ASPR (3 awards, $73.6 million combined potential value), signaling Sagent's role in federal emergency-preparedness and disease-response pharmaceutical stockpiling. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 accounts for 11 awards worth $27.7 million. These five customers represent virtually 100% of tracked award activity.
Sagent holds two major vehicle positions. An indefinite delivery contract (SPE2D021D0003) with DLA Troop Support Medical carries 216 task orders and $1.9 million combined potential value, serving as the backbone for recurring small-order pharmaceutical delivery. A second indefinite delivery contract (SPM2D013D0001) holds 86 task orders worth $9.5 million. A $5.5 million Federal Supply Schedule contract (Pharmaceuticals and Drugs FSS-61-IB) awarded May 1, 2024, through April 30, 2029, under the Veterans Integrated Service Network 12 administering office provides additional ordering capacity for injectable drugs and pharmaceutical products on a multiple-award basis. An HHS indefinite delivery contract (HHSD200201587789I) carries 6 task orders valued at $43 million, anchoring the larger disaster-response and stockpile work.
Activity accelerated in 2023–2024, with 50 awards in 2023 declining to 25 in 2024, then recovering to 33 in 2025 and 37 in 2026. Only one award (potential value $149 thousand) completes within the next twenty-four months, indicating minimal near-term recompete exposure. Sagent operates exclusively as a prime contractor; no subcontract work appears in the source. The company manufactures at its Schaumburg facility with performance documented across that location and subordinate Hoffman Estates operations, serving military treatment facilities, federal health agencies, and strategic stockpile fulfillment nationwide.
Quick answers
Is Sagent Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Sagent Pharmaceuticals, Inc.'s SAM.gov registration is active through February 2, 2027.
Which contract vehicles does Sagent Pharmaceuticals, Inc. hold?
Sagent Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Sagent Pharmaceuticals, Inc. received in federal contracts?
Federal contracts obligated $16,741,169 to Sagent Pharmaceuticals, Inc. in fiscal year 2025 and $17,577,606 in fiscal years 2023 through 2027.
How does Sagent Pharmaceuticals, Inc. rank among federal contractors?
Sagent Pharmaceuticals, Inc. ranked #18 in NAICS 325412, #23 in PSC 6505 and #24 in NAICS 3254 in FY2025.
What is Sagent Pharmaceuticals, Inc.'s most recent federal award?
Sagent Pharmaceuticals, Inc.'s most recent federal contract award is Ciprofloxaxin ivpb (36C77026P0086), from Veterans Integrated Service Network 15 (VHA), on August 14, 2026.
On GovTribe
See Sagent Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors